DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects

Dasu, M. R., Devaraj, S., Park, S., & Jialal, I. (2010) · Diabetes Care · doi:10.2337/dc09-1799 · Cited by 572 · see citing works

Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV

Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., Asakawa, T., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070104l · Cited by 409 · see citing works

Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 384 · see citing works

CD26: a surface protease involved in T-cell activation

Fleischer, B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90316-6 · Cited by 329 · see citing works

Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer

Lehr, H., Mankoff, D. A., Corwin, D., Santeusanio, G., & Gown, A. M. (1997) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549704501112 · Cited by 308 · see citing works

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

DeFronzo, R. A., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227 · see citing works

TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis

Michelsen, K. S., Doherty, T. M., Shah, P. K., & Arditi, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5901 · Cited by 211 · see citing works

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

Ferreira, L., Teixeira‐Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R. M. A., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 195 · see citing works

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173 · see citing works

Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice

Lin, R.-Y., Choudhury, R. P., Cai, W., Lu, M. M., Fallon, J. T., Fisher, E. A. A., & Vlassara, H. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00050-9 · Cited by 171 · see citing works

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Pratley, R. E., Reusch, J. E. B., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 009 Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903156111 · Cited by 132 · see citing works

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X. M., Bollaert, W., Lambeir, A., Durinx, C., Goossens, F. J., & Haemers, A. (1999) · PubMed · Cited by 131 · see citing works

Expression of Interleukin-6 in Atherosclerotic Lesions of Male ApoE-Knockout Mice

Sukovich, D. A., Kauser, K. Z., Shirley, F. D., DelVecchio, V., Halks‐Miller, M., & Rubanyi, G. M. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1498 · Cited by 125 · see citing works

The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors

Augustyns, K., Bala, G., Thonusa, G., Belyaeva, A., Zhanga, X. M., Bollaerta, W., Lambeirb, A. M., Durinxb, C., Goossensb, F., & Haemersa, A. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220208213543 · Cited by 125 · see citing works

Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice

Lassila, M., Jandeleit-Dahm, K. A. M., Seah, K. K., Smith, C. M., Calkin, A. C., Allen, T. J., & Cooper, M. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050392 · Cited by 117 · see citing works

Functional role of CD26 on human B lymphocytes

Bühling, F., Junker, U., Reinhold, D., Neubert, K., Jäger, L., & Ansorge, S. (1995) · Immunology Letters · doi:10.1016/0165-2478(94)00230-o · Cited by 112 · see citing works

Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques?

Kanter, J. E., Johansson, F., LeBoeuf, R. C., & Bornfeldt, K. (2007) · Circulation Research · doi:10.1161/01.res.0000259589.34348.74 · Cited by 112 · see citing works

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

Gupta, R., Walunj, S. S., Tokala, R. K., Parsa, K. V. L., Singh, S. K., & Pal, M. (2009) · Current Drug Targets · doi:10.2174/138945009787122860 · Cited by 105 · see citing works

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

Ta, N., Li, Y., Schuyler, C. A., Lopes-Virella, M. F., & Huang, Y. Q. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.064 · Cited by 96 · see citing works

Lipopolysaccharide and Peptidoglycan: CD14-Dependent Bacterial Inducers of Inflammation

Rietschel, E., Schletter, J., Weidemann, B., El‐Samalouti, V. T., Mattern, T., Zähringer, U., Seydel, U., Brade, H., Flad, H.-D., Kusumoto, S., et al. (1998) · Microbial Drug Resistance · doi:10.1089/mdr.1998.4.37 · Cited by 89 · see citing works

Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17β-estradiol

Tse, J., Martin-McNulty, B., Halks‐Miller, M., Kauser, K. Z., DelVecchio, V., Vergona, R. A., Sullivan, M. E., & Rubanyi, G. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00325-6 · Cited by 84 · see citing works

Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase

Hegen, M., Kameoka, J., Dong, R., Schlossman, S. F., & Morimoto, C. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00053.x · Cited by 78 · see citing works

Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)

Saremi, A., Anderson, R. J., Luo, P., MORITZ, T. E., Schwenke, D. C., Allison, M., & Reaven, P. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.031 · Cited by 77 · see citing works

Why does diabetes increase atherosclerosis? I don’t know!

Goldberg, I. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22826 · Cited by 64 · see citing works

Alogliptin

Scott, L. J. (2010) · Drugs · doi:10.2165/11205080-000000000-00000 · Cited by 62 · see citing works

Inhibitors of Dipeptidyl Peptidase IV (DP IV, CD26) Specifically Suppress Proliferation and Modulate Cytokine Production of Strongly CD26 Expressing U937 Cells

Reinhold, D., Bank, U., Bühling, F., Kähne, T., Kunt, D., Faust, J., Neubert, K., & Ansorge, S. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80412-2 · Cited by 58 · see citing works

Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice

Zhang, X., Wang, Z., Huang, Y. Q., & Wang, J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01354.x · Cited by 57 · see citing works

Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose

Hayek, T., Hussein, K., Aviram, M., COLEMAN, R., Keidar, S., PAVOLTZKY, E., & KAPLAN, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.02.018 · Cited by 54 · see citing works

Combination treatment with alogliptin and voglibose increases active GLP‐1 circulation, prevents the development of diabetes and preserves pancreatic beta‐cells in prediabetic db/db mice

Moritoh, Y., Takeuchi, K., & Hazama, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01156.x · Cited by 49 · see citing works

High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor κB and AP-1 activities

Nareika, A., Im, Y., Game, B. A., Slate, E. H., Sanders, J. J., London, S. D., Lopes-Virella, M. F., & Huang, Y. Q. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0145 · Cited by 47 · see citing works

Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide

Jungraithmayr, W., Meester, I. D., Matheeussen, V., İnci, İ., Augustyns, K., Scharpé, S., Weder, W., & Korom, S. (2009) · Peptides · doi:10.1016/j.peptides.2009.12.012 · Cited by 46 · see citing works

Cardiovascular outcomes among participants with diabetes in the recent large statin trials

Armitage, J., & Bowman, L. J. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137219.31407.16 · Cited by 35 · see citing works

Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes

Reinhold, D., Vetter, R., Mnich, K., Bühling, F., Lendeckel, U., Born, I., Faust, J., Neubert, K., Gollnick, H. P. M., & Ansorge, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00502-x · Cited by 35 · see citing works

Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation

Sundararaj, K. P., Samuvel, D. J., Li, Y., Nareika, A., Slate, E. H., Sanders, J. J., Lopes-Virella, M. F., & Huang, Y. Q. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0108064 · Cited by 35 · see citing works

Relation between interleukin-6 level and subclinical intracranial large-artery atherosclerosis

Hoshi, T., Kitagawa, K., Yamagami, H., Furukado, S., Hougaku, H., & Hori, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.013 · Cited by 35 · see citing works

Pre‐exposure to high glucose augments lipopolysaccharide‐stimulated matrix metalloproteinase‐1 expression by human U937 histiocytes

Maldonado, A., He, L., Game, B. A., Nareika, A., Sanders, J. J., London, S. D., Lopes-Virella, M. F., & Huang, Y. Q. (2004) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2004.00756.x · Cited by 30 · see citing works

Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice

Goldberg, I. J., Isaacs, A. J., Sehayek, E., Breslow, J. L., & Huang, L.-S. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.09.014 · Cited by 20 · see citing works

Human mononuclear phagocyte-associated antigens

Waldrep, J. C., Mohanakumar, T., & Kaplan, A. M. (1981) · Cellular Immunology · doi:10.1016/0008-8749(81)90307-5 · Cited by 17 · see citing works

Administration of Pioglitazone in Low-Density Lipoprotein Receptor-Deficient Mice Inhibits Lesion Progression and Matrix Metalloproteinase Expression in Advanced Atherosclerotic Plaques

He, L., Game, B. A., Nareika, A., Garvey, W. T., & Huang, Y. Q. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000248831.21973.c4 · Cited by 16 · see citing works

The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis

Wierzbicki, A. S., Morrell, J., Hemsley, D., McMahon, Z., Crook, M. A., & Wray, R. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.503429 · Cited by 13 · see citing works

The PROactive study: Pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes

Pratley, R. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0051-6 · Cited by 10 · see citing works

Eplerenone does not attenuate diabetes-associated atherosclerosis

Koh., P. J., Koı̈tka, A., Cooper, M. E., & Allen, T. J. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832bd284 · Cited by 7 · see citing works

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas

Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247 · see citing works

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease

Zhong, J., Rao, X., & Rajagopalan, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 209 · see citing works

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A., & Meester, I. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00387 · Cited by 194 · see citing works

DPP4 in Cardiometabolic Disease

Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190 · see citing works

Cardiovascular effects of gliptins

Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175 · see citing works

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE ^−/− mouse model

Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148 · see citing works

Hypoglycemic agents and potential anti-inflammatory activity

Mathews, S. T., Kothari, V. M., & Galdo, J. A. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86917 · Cited by 131 · see citing works

Toll-Like Receptors in Atherosclerosis

Falck-Hansen, M., Kassiteridi, C., & Monaco, C. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714008 · Cited by 125 · see citing works

The potential for renoprotection with incretin-based drugs

Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 122 · see citing works

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W.-W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122 · see citing works

Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system

Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 112 · see citing works

Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation

Fuentes‐Antrás, J., Ioan, A.-M., Tuñón, J., Egido, J., & Lorenzo, Ó. (2014) · International Journal of Endocrinology · doi:10.1155/2014/847827 · Cited by 95 · see citing works

Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?

Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91 · see citing works

Toll-like receptors: sensing and reacting to diabetic injury in the kidney

Lin, M., & Tang, S. C. W. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft446 · Cited by 86 · see citing works

Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection

Tomović, K., Lazarević, J., Kocic, G., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal research reviews (Print) · doi:10.1002/med.21513 · Cited by 84 · see citing works

Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis

Matheeussen, V., Waumans, Y., Martinet, W., Goethem, S. V., der Veken, P. V., Scharpé, S., Augustyns, K., Meyer, G. R. Y. D., & Meester, I. D. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0350-4 · Cited by 85 · see citing works

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes

Singh, A.-K., Yadav, D., Sharma, N., & Jin, J. (2021) · Pharmaceuticals · doi:10.3390/ph14060586 · Cited by 83 · see citing works

Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

Esposito, G., Cappetta, D., Russo, R., Rivellino, A., Ciuffreda, L. P., Roviezzo, F., Piegari, E., Berrino, L., Rossi, F., Angelis, A. D., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13686 · Cited by 80 · see citing works

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors

Kim, N.-H., Yu, T., & Lee, D. H. (2014) · BioMed Research International · doi:10.1155/2014/368703 · Cited by 79 · see citing works

TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice

Lu, Z., Zhang, X., Li, Y., Jin, J., & Huang, Y. Q. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0338 · Cited by 78 · see citing works

DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages

Brenner, C., Franz, W.-M., Kühlenthal, S., Kuschnerus, K., Remm, F., Gross, L., Theiss, H. D., Landmesser, U., & Kränkel, N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.044 · Cited by 78 · see citing works

A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression

Hwang, H.-J., Jung, T. W., Kim, B.-H., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.098 · Cited by 72 · see citing works

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice

Terasaki, M., Nagashima, M., Nohtomi, K., Kohashi, K., Tomoyasu, M., Shinmura, K., Nogi, Y., Katayama, Y., Sato, K., Itoh, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070933 · Cited by 71 · see citing works

DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome

Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 70 · see citing works

Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury

Matheeussen, V., Jungraithmayr, W., & Meester, I. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.012 · Cited by 65 · see citing works

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation

Ikedo, T., Minami, M., Kataoka, H., Hayashi, K., Nagata, M., Fujikawa, R., Higuchi, S., Yasui, M., Aoki, T., Fukuda, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004777 · Cited by 64 · see citing works

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials

Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 60 · see citing works

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease

Panchapakesan, U., Mather, A., & Pollock, C. A. (2012) · Clinical Science · doi:10.1042/cs20120167 · Cited by 58 · see citing works

Targeting Immune Senescence in Atherosclerosis

Vellasamy, D. M., Lee, S.-J., Goh, K. W., Goh, B. H., Tang, Y.-Q., Ming, L. C., & Yap, W. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113059 · Cited by 60 · see citing works

Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways

El-Sahar, A. E., Shiha, N. A., Sayed, N. S. E., & Ahmed, L. A. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa078 · Cited by 59 · see citing works

The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis

Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59 · see citing works

DPP4 Activity, Hyperinsulinemia, and Atherosclerosis

Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 55 · see citing works

Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals

Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 49 · see citing works

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial

Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51 · see citing works

Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond

Fadini, G. P., & Avogaro, A. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.007 · Cited by 52 · see citing works

DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Henry-Smith, C. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165933 · Cited by 50 · see citing works

DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes

Aroor, A. R., McKarns, S. C., Nistala, R., DeMarco, V. G., Gardner, M., Garcia‐Touza, M., Whaley‐Connell, A. T., & Sowers, J. R. (2013) · Cardiorenal Medicine · doi:10.1159/000348756 · Cited by 49 · see citing works

Anti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes

Nakamura, Y., Tsuji, M., Hasegawa, H., Kimura, K., Fujita, K., Inoue, M., Shimizu, T., Gotoh, H., Goto, Y., Inagaki, M., et al. (2014) · Hemodialysis International · doi:10.1111/hdi.12127 · Cited by 46 · see citing works

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence

Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46 · see citing works

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain

Király, K. P., Kozsurek, M., Lukácsi, E., Barta, B., Alpár, A., Balázsa, T., Fekete, C., Szabon, J., Helyes, Z., Bölcskei, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21799-8 · Cited by 46 · see citing works

Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection

Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 45 · see citing works

Atherosclerosis

Aviram, M. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283513594 · Cited by 43 · see citing works

Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches

Heinonen, S. E., Genové, G., Bengtsson, E., Hübschle, T., Åkesson, L., Hiss, K., Benardeau, A. M., Ylä‐Herttuala, S., Jönsson‐Rylander, A., & Gomez, M. F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/404085 · Cited by 42 · see citing works

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

Akita, K., Isoda, K., Shimada, K., & Daida, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001469 · Cited by 42 · see citing works

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

Wang, M.-T., Lin, S., Tang, P., Hung, W.-T., Cheng, C.-C., Yang, J.-S., Chang, H., Liu, C., Mar, G.-Y., & Huang, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0572-0 · Cited by 41 · see citing works

The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice

Waumans, Y., Vliegen, G., Maes, L., Rombouts, M., Declerck, K., der Veken, P. V., Berghe, W. V., Meyer, G. R. Y. D., Schrijvers, D. M., & Meester, I. D. (2015) · Inflammation · doi:10.1007/s10753-015-0263-5 · Cited by 38 · see citing works

Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients

Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 37 · see citing works

Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?

Desouza, C. V. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.007 · Cited by 36 · see citing works

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

Rizzo, M., Nikolić, D., Banach, M., Patti, A. M., Montalto, G., & Rizvi, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206102255 · Cited by 36 · see citing works

Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits

Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 36 · see citing works

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin

Aroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 37 · see citing works

A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression

Terasaki, M., Yashima, H., Mori, Y., Saito, T., Matsui, T., Hiromura, M., Kushima, H., Osaka, N., Ohara, M., Fukui, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134811 · Cited by 35 · see citing works

Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors

Nakamura, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.840 · Cited by 34 · see citing works

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients

Chang, C. C., Chen, Y., Hsu, C., Su, Y., Chiu, C.-C., Leu, H., Huang, P., Chen, J., & Lin, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.10.016 · Cited by 34 · see citing works

Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages

Hiromura, M., Nohtomi, K., Mori, Y., Kataoka, H., Sugano, M., Ohnuma, K., Kuwata, H., & Hirano, T. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.016 · Cited by 34 · see citing works

Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning

Rameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34 · see citing works

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

Shigematsu, E. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1889w · Cited by 33 · see citing works

Understanding the intricacies of cellular senescence in atherosclerosis: Mechanisms and therapeutic implications

Ali, I., Zhang, H., Zaidi, S. A. A., & Zhou, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102273 · Cited by 34 · see citing works

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients

Du, H., Wang, D. W., & Chen, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15674 · Cited by 32 · see citing works

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes

Koška, J., Sands, M. A., Burciu, C., & Reaven, P. D. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114562411 · Cited by 31 · see citing works

Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials

Balakumar, P., & Dhanaraj, S. A. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.009 · Cited by 31 · see citing works

Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease

Remm, F., Franz, W., & Brenner, C. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv044 · Cited by 31 · see citing works

The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes

Lee, T.-I., Kao, Y.-H., Chen, Y.-C., Huang, J.-H., Hsu, M., & Chen, Y.-J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.051 · Cited by 30 · see citing works

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30 · see citing works

A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice

Kohashi, K., Hiromura, M., Mori, Y., Terasaki, M., Watanabe, T., Kushima, H., Shinmura, K., Tomoyasu, M., Nagashima, M., & Hirano, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31997 · Cited by 30 · see citing works

GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells

Hu, Y., Liu, H. B., Simpson, R. W., & Dear, A. E. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2290-8 · Cited by 29 · see citing works

DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation

Hu, X., Liu, S., Liu, X., Zhang, J., Liang, Y. J., & Yan, L. (2016) · Endocrine · doi:10.1007/s12020-016-1073-8 · Cited by 29 · see citing works

miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease

Eken, S. M., Christersdottir, T., Winski, G., Sangsuwan, T., Jin, H. H., Chernogubova, E., Pirault, J., Sun, C., Simon, N. L., Winter, H., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.006 · Cited by 28 · see citing works

The Anti-Inflammatory Effect of Novel Antidiabetic Agents

Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 31 · see citing works

Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease

Yang, G., Li, Y.-Z., Cui, L., Jiang, H., Li, X., Jin, C., Jin, D., Zhao, G., Jin, J., Sun, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163027 · Cited by 25 · see citing works

Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes

Guo, Q., Zhang, S., Huang, J., & Liu, K. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106372 · Cited by 25 · see citing works

Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease

Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 25 · see citing works

DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives

Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 25 · see citing works

Coronavirus Receptors as Immune Modulators

Devarakonda, C. K. V., Meredith, E. K., Ghosh, M., & Shapiro, L. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001062 · Cited by 22 · see citing works

Incretin hormones as immunomodulators of atherosclerosis

Alonso, N., Julián, M. T., Puig‐Domingo, M., & Vives‐Pi, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00112 · Cited by 23 · see citing works

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

Lim, S. W., Jin, J. Z., Jin, L. G., Jin, J., & Li, C. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.759 · Cited by 23 · see citing works

Hypertension in diabetes care: emerging roles of recent hypoglycemic agents

Tanaka, A., & Node, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00665-7 · Cited by 21 · see citing works

Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus

Yang, L., Yuan, J., & Zhou, Z. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.008 · Cited by 21 · see citing works

RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy

Olejarz, W., Łacheta, D., Głuszko, A., Migacz, E., Kukwa, W., Szczepański, M. J., Tomaszewski, P., & Nowicka, G. (2018) · BioMed Research International · doi:10.1155/2018/7675286 · Cited by 21 · see citing works

Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice

Lin, C.-P., Huang, P., Chen, C., Wu, M., Chen, J.-S., Chen, J., & Lin, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97361-w · Cited by 20 · see citing works

Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review

Singh, T. P., Vangaveti, V., & Malabu, U. H. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.005 · Cited by 20 · see citing works

Potential cardiovascular effects of incretin-based therapies

Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19 · see citing works

Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study

Iwakura, T., Fukasawa, H., Kitamura, A., Ishibuchi, K., Yasuda, H., & Furuya, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229377 · Cited by 19 · see citing works

Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

Katakami, N., Mita, T., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.18333 · Cited by 18 · see citing works

Alogliptin benzoate for management of type 2 diabetes

Saisho, Y. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s68564 · Cited by 18 · see citing works

Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes

Li, B., Luo, Y., Tian, F., Chen, Y., Tian, J., Ding, Y., Mei, Z., Li, J., Zhang, Y.-Q., & Shi, W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.015 · Cited by 17 · see citing works

Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties

Kutoh, E., Kaneoka, N., & Hirate, M. (2014) · Endocrine Research · doi:10.3109/07435800.2014.952743 · Cited by 17 · see citing works

Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes

Yamadera, S., Nakamura, Y., Inagaki, M., Kenmotsu, S., Nohara, T., Sato, N., Oguchi, T., Tsuji, M., Ohsawa, I., Gotoh, H., et al. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0071-z · Cited by 17 · see citing works

Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice

Aini, K., Fukuda, D., Tanaka, K., Higashikuni, Y., Hirata, Y., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2019) · International Heart Journal · doi:10.1536/ihj.19-117 · Cited by 18 · see citing works

Cardiovascular protective properties of incretin-based therapies in type 2 diabetes

Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 16 · see citing works

Alogliptin benzoate for the treatment of type 2 diabetes

Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 15 · see citing works

Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis

Lv, Q., Yang, Y., Lv, Y., Wu, Q., Hou, X.-Z., Li, L., Ye, X., Yang, C., & Wang, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1403606 · Cited by 15 · see citing works

Targeting senescent cells in atherosclerosis: Pathways to novel therapies

Tian, Y., Shao, S., Feng, H., Zeng, R., Li, S., & Zhang, Q. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102502 · Cited by 15 · see citing works

Saxagliptin protects against hypoxia-induced damage in H9c2 cells

Zhang, L., Qi, X., Zhang, G., Zhang, Y., & Tian, J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108864 · Cited by 14 · see citing works

Diabetes medications and cardiovascular outcome trials: Lessons learned

Patel, K. V., Rocha, N. D. A., & McGuire, D. K. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17006 · Cited by 14 · see citing works

Consumption of Amaranth Induces the Accumulation of the Antioxidant Protein Paraoxonase/Arylesterase 1 and Modulates Dipeptidyl Peptidase IV Activity in Plasma of Streptozotocin-Induced Hyperglycemic Rats

Velarde‐Salcedo, A. J., Regalado-Rentería, E., Velarde-Salcedo, R., Juárez-Flores, B. I., Barrera-Pacheco, A., de Mejı́a, E. G., & de la Rosa, A. P. B. (2017) · Lifestyle Genomics · doi:10.1159/000486482 · Cited by 14 · see citing works

Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach

Dai, Y., Dai, D., Mercanti, F., Ding, Z., Wang, X., & Mehta, J. L. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0496-4 · Cited by 13 · see citing works

Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus

Davidson, M. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2756 · Cited by 13 · see citing works

Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study

Vangaveti, V., Jhamb, S., Hayes, O., Goodall, J., Bulbrook, J., Robertson, K., Biroš, E., Sangla, K. S., & Malabu, U. H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00938-2 · Cited by 13 · see citing works

The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety

Green, J. B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2566 · Cited by 12 · see citing works

A DPP-4 inhibitor, alogliptin, improved hypertriglyceridemia but had no effect on atherosclerosis in apoE KO mice, Independent of renal function

Katayama, K., Umebayashi, R., Asakawa, T., Sakurabu, Y., Onishi, Y., Uchiyama-Matsuoka, N., Takeuchi, H., Uchida, H. A., & Wada, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119718

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice

Terasaki, M., Nagashima, M., Nohtomi, K., Kohashi, K., Tomoyasu, M., Shinmura, K., Nogi, Y., Katayama, Y., Sato, K., Itoh, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070933 · Cited by 71 · see citing works

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 152 · see citing works

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte

Maiseyeu, A., & Rajagopalan, P. S. (2016)

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W.-W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122 · see citing works